Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Hoechst/Andrx Cardizem CD Settlement Is Antitrust Violation - Biovail

  • News

Executive Summary

Hoechst Marion Roussel's settlement with Andrx over a generic version of Cardizem CD is part of a pattern of antitrust violations by Hoechst, Biovail claimed in a March 30 suit filed in Newark, N.J. federal court.

You may also be interested in...



Aventis/Andrx Cardizem CD Deal Violated Antitrust Laws, Judge Says

Andrx and Aventis violated federal antitrust laws by entering an agreement aimed to keep all generic Cardizem CD products off the market, a June 6 Detroit federal court summary judgement maintains.

Aventis/Andrx Cardizem CD Deal Violated Antitrust Laws, Judge Says

Andrx and Aventis violated federal antitrust laws by entering an agreement aimed to keep all generic Cardizem CD products off the market, a June 6 Detroit federal court summary judgement maintains.

FTC Hytrin Order Clears Path For Four Generics; Cardizem CD Case Filed

Geneva's settlement with the Federal Trade Commission regarding generic terazosin (Hytrin) could open up the market for up to four new entrants.

Table

View full table

Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS031984

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By